Tim Mcintire Email & Phone Number

Cambridge, Massachusetts

Cambridge, Ma

Commercial lead for the fitusiran (ALN-AT3) program responsible for the planning and execution of all brand development, market preparation and launch readiness activities. Key responsibilities include development of the 5-year strategic plan, cross functional team leadership and alignment, brand positioning, tactical development and execution and management of the commercial relationship with Genzyme.

• Developed global brand positioning, messaging, packaging and core materials for the successful launch of ELOCTATE.• Led the long-term differentiation project which resulted in the successful updating of the core message platform, story and campaign in anticipation of competitive long-acting factor launches.• Developed the cross functional competitive readiness plans for Nuwiq, Adynovate, BAY 94-9027 and Novo 8-GP to ensure continued success of ELOCTATE.• Led the development of the functional 2016 – 2020 global strategic marketing plan ensuring alignment across the functions and between Sobi and Biogen.• Provided commercial leadership for the program team which included the development and approval of the life cycle management plan. Plan included six newly approved initiatives to further optimize launch performance of the hemophilia franchise.• Led commercial activities for the hemophilia life cycle management plan.• Led the commercial launch planning team and all commercial activities associated with affiliate launches. ELOCTATE was successfully launched in US and Japan and approved in Canada and Australia.• Commercial lead for the strategic labeling team and Core Data Sheet development to ensure optimized and consistent labeling across markets.• Successfully developed and executed multiple strategic commercial advisory boards and symposium.• ELOCTATE performing at budget in both US and Japan.

Weston

• Developed global brand positioning, messaging, packaging and core materials for the successful launch of ALPROLIX.• Led the development of the 2012 Annual Operating Plan endorsed by executive leadership.• Commercial lead for the cross-functional rFIXFc Program Team.

• Responsible for all global brand management strategic activities for BeneFIX and ReFacto AF-Xyntha.• Franchise exceeded $1 billion in net revenues in 2010 for the first time.o Franchise 106% of goal / BeneFIX 103% of goal, 10% YOY growth / ReFacto AF-Xyntha 111% of goal, 18% YOY growth• BeneFIX approved in 3 new markets in 2010, introduced BeneFIX reformulated successfully launched in 3 existing markets.• ReFacto AF-Xyntha approved in 7 new markets in 2010.• Led all aspects in gaining Specialty Care Business Unit endorsement of five key life cycle projects.• Implemented and led cross-functional Asset Teams for BeneFIX and ReFacto AF-Xyntha.• Developed and executed franchise vision, positioning and campaign to introduce Pfizer Hemophilia.

• Increased brand performance 8% reversing a negative sales trend of 15% for the previous twelve months through the successful development and execution of differentiated positioning, messaging and campaign to support the US launch of Xyntha in August 2008.• Exceeded all key US launch objectives for patient conversion and new patient initiation by increasing patient acquisition seven fold, reversing a negative trend over the previous 15 months.• Transitioned 97% of current US ReFacto patients to Xyntha by implementing novel relationship marketing activities including first-in-company programming on YouTube.• Led the execution of global positioning, messaging and campaign execution to ensure harmonization and consistency in the branding of ReFacto AF and Xyntha. • Achieved European Commission approval for ReFacto AF as the commercial lead of a multi-functional team responsible for the development and execution of an alternative filing strategy.• Created a net after tax benefit of $5 million for the corporation by developing and executing a creative product donation plan which also provided a humanitarian benefit for patients in underserved markets.• Commercial lead to the US and Global product labeling teams to ensure that Xyntha and ReFacto AF product labels were competitive and allowed for differentiated product promotion.

• Developed a novel tool and approach of assessing potential in-licensing and co-marketing product candidates which was adopted by the Therapeutic Teams which I participated. • Led a multidisciplinary in-licensing team which led to the identification, commercial assessment and external partnership for a novel antipsychotic agent.• Commercial lead for co-promotion and product acquisition discussions with Novartis, BMS, Astra-Zeneca, Almirall Prodesfarma and Merkle.

• Provided strategic oversight to assist in the development and implementation of the Collaborative Solutions Campaign which increased the growth of Premarin® in key accounts by 40 percent.• Successfully launched Enbrel, Sonata, Effexor XR and Synvisc in managed accounts based on formulary acceptance, product adoption and market share.• Led a multidisciplinary team in the development and implementation of a retail conversion program for a newly introduced once-daily NSAID.